secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001104659-22-114234
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Q3 net loss widens to $7.8M; raises $10.7M in October financing
-------------------------------------------------------------------------

- Net loss Q3 2022: ($7.8M) or ($1.28)/share vs ($5.8M) ($0.97)/share in Q3 2021.
- Cash and equivalents $17.8M at Sep 30, 2022, down from $35.7M at Dec 31, 2021.
- Closed $10.7M gross proceeds from registered direct and private placement in October.
- R&D expense $5.4M (up from $3.9M) driven by Waldenstrom's macroglobulinemia pivotal trial.
- Awarded $2M NCI grant to expand Phase 1 pediatric brain tumor trial to Phase 1b.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/0001104659-22-114234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/tm2229607d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer